Amended Statement of Beneficial Ownership (sc 13d/a)
June 01 2022 - 6:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 6)*
Kala Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.001
per share
(Title of Class of Securities)
483119103
(CUSIP Number)
RA Capital Management, L.P.
200 Berkeley Street, 18th Floor
Boston, MA 02116
Telephone: 617.778.2500
Attn: Peter Kolchinsky
(Name, Address and Telephone Number of Person Authorized
to
Receive Notices and Communications)
May 26, 2022
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. ¨
Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing
information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 483119103
1 |
Names of Reporting Persons.
RA Capital Management, L.P.
|
2 |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
(a) ¨ |
|
(b) ¨ |
3 |
SEC Use Only |
4 |
Source of Funds (See Instructions):
AF
|
5 |
Check if disclosure of legal proceedings is required
pursuant to Items 2(d) or 2(e):
¨
|
6 |
Citizenship or Place of Organization. Delaware
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 Sole Voting Power 0 shares
|
8 Shared Voting Power 6,194,789
shares
|
9 Sole Dispositive Power 0 shares
|
10 Shared
Dispositive Power 6,194,789 shares
|
11 |
Aggregate Amount Beneficially Owned by Each Reporting
Person
6,194,789
shares |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
|
13 |
Percent of Class Represented by Amount in Row
(11)
8.53%1 |
|
14 |
Type of Reporting Person (See Instructions)
IA, PN
|
|
|
|
|
|
1 The reporting person is the beneficial owner of 6,194,789
shares of the Issuer’s Common Stock which constitute approximately 8.53% of the class outstanding. The percentage calculation
assumes that there are currently 72,634,005 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as
filed with the Securities and Exchange Commission (“SEC”) on May 16, 2022 and giving effect to 40,000 vested Restricted Share
Units issued to Mr. Rajeev Shah for the benefit of RA Capital.
CUSIP No. 483119103
1 |
Names of Reporting Persons.
Peter Kolchinsky
|
2 |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
(a) ¨ |
|
(b) ¨ |
3 |
SEC Use Only |
4 |
Source of Funds (See Instructions):
AF
|
5 |
Check if disclosure of legal proceedings is required
pursuant to Items 2(d) or 2(e):
¨
|
6 |
Citizenship or Place of Organization. United
States
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 Sole Voting Power 0 shares
|
8 Shared Voting Power 6,194,789
shares
|
9 Sole Dispositive Power 0 shares
|
10 Shared
Dispositive Power 6,194,789 shares
|
11 |
Aggregate Amount Beneficially Owned by Each Reporting
Person
6,194,789
shares |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
|
13 |
Percent of Class Represented by Amount in Row
(11)
8.53%2 |
|
14 |
Type of Reporting Person (See Instructions)
HC, IN
|
|
|
|
|
|
2 The reporting person is the beneficial owner of 6,194,789 shares of the
Issuer’s Common Stock which constitute approximately 8.53% of the class outstanding. The percentage calculation assumes that there
are currently 72,634,005 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities
and Exchange Commission (“SEC”) on May 16, 2022 and giving effect to 40,000 vested Restricted Share Units issued to Mr. Rajeev
Shah for the benefit of RA Capital.
CUSIP No. 483119103
1 |
Names of Reporting Persons.
Rajeev Shah
|
2 |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
(a) ¨ |
|
(b) ¨ |
3 |
SEC Use Only |
4 |
Source of Funds (See Instructions):
AF
|
5 |
Check if disclosure of legal proceedings is required
pursuant to Items 2(d) or 2(e):
¨
|
6 |
Citizenship or Place of Organization. United
States
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 Sole Voting Power 0 shares
|
8 Shared Voting Power 6,194,789
shares
|
9 Sole Dispositive Power 0 shares
|
10 Shared
Dispositive Power 6,194,789 shares
|
11 |
Aggregate Amount Beneficially Owned by Each Reporting
Person
6,194,789
shares |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
|
13 |
Percent of Class Represented by Amount in Row
(11)
8.53%3 |
|
14 |
Type of Reporting Person (See Instructions)
HC, IN
|
|
|
|
|
|
3 The reporting person is the beneficial owner of 6,194,789 shares of the
Issuer’s Common Stock which constitute approximately 8.53% of the class outstanding. The percentage calculation assumes that there
are currently 72,634,005 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities
and Exchange Commission (“SEC”) on May 16, 2022 and giving effect to 40,000 vested Restricted Share Units issued to Mr. Rajeev
Shah for the benefit of RA Capital..
CUSIP No. 483119103
1 |
Names of Reporting Persons.
RA Capital Healthcare Fund, L.P.
|
2 |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
(a) ¨ |
|
(b) ¨ |
3 |
SEC Use Only |
4 |
Source of Funds (See Instructions):
WC
|
5 |
Check if disclosure of legal proceedings is required
pursuant to Items 2(d) or 2(e):
¨
|
6 |
Citizenship or Place of Organization. United
States
|
Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With |
7 Sole Voting Power 0 shares
|
8 Shared Voting Power 6,194,789
shares
|
9 Sole Dispositive Power 0 shares
|
10 Shared
Dispositive Power 6,194,789 shares
|
11 |
Aggregate Amount Beneficially Owned by Each Reporting
Person
6,194,789
shares |
|
12 |
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ¨ |
|
13 |
Percent of Class Represented by Amount in Row
(11)
8.53%4 |
|
14 |
Type of Reporting Person (See Instructions)
PN
|
|
|
|
|
|
4 The reporting
person is the beneficial owner of 6,194,789 shares of the Issuer’s Common Stock which
constitute approximately 8.53% of the class outstanding. The percentage calculation assumes that there are currently 72,634,005 outstanding
shares of Common Stock of the Issuer, based on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission (“SEC”)
on May 16, 2022 and giving effect to 40,000 vested Restricted Share Units issued to Mr. Rajeev Shah for the benefit of RA Capital..
CUSIP No. 483119103
SCHEDULE 13D
| Item 1. | Security and Issuer |
Item 1 of the Statement is hereby amended and
supplemented as follows:
This Amendment No. 6 amends and supplements the
statement on Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on February 14, 2018, as
amended by Amendment No. 1 filed on October 5, 2018, Amendment No. 2 filed on March 13, 2020, Amendment No. 3 filed on October 25, 2021,
Amendment No. 4 filed on April 1, 2022, and Amendment No. 5 filed on May 25, 2022 (the “Statement”) by RA Capital Management,
L.P., Dr. Kolchinsky, and Mr. Shah with respect to the common stock, par value $0.001 per share (the “Common Stock”), of Kala
Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”) and serves as the initial Schedule 13D for RA Capital Healthcare
Fund, L.P. (the “Fund”). Unless otherwise defined herein, capitalized terms used in this Amendment No. 6 shall have the meanings
ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
| Item 5. | Interest in Securities of the Issuer |
Item 5 of the Statement is hereby amended and
supplemented as follows:
(a) and (b) See Items 7-11 of the cover pages
and Item 2 above.
(c) Schedule A
sets forth all transactions with respect to the shares of Common Stock effected during the past sixty days by any Reporting Person and
is incorporated herein by reference.
(d) Not applicable.
(e) Not applicable.
CUSIP No. 483119103
SIGNATURES
After reasonable inquiry and
to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RA CAPITAL MANAGEMENT, L.P.
| Title: | Authorized Signatory |
PETER KOLCHINSKY
/s/ Peter Kolchinsky
RAJEEV SHAH
/s/ Rajeev Shah
RA CAPITAL HEALTHCARE FUND, L.P.
| By: | RA Capital Healthcare Fund GP, LLC |
CUSIP No. 483119103
Schedule A
|
|
Number of Shares
Acquired / (Disposed)
|
|
|
|
|
|
|
|
RA Capital Healthcare Fund, L.P. |
05/26/22 |
1,005,686
Common Stock |
Sale |
$0.306 |
|
|
|
|
|
RA Capital Healthcare Fund, L.P. |
05/27/22 |
500,000
Common Stock |
Sale |
$0.517 |
|
|
|
|
|
RA Capital Healthcare Fund, L.P. |
05/31/22 |
344,824
Common Stock |
Sale |
$0.358 |
|
|
|
|
|
6 This transaction was executed in multiple trades at prices
ranging from $0.35 to $0.39; the price reported above reflects the weighted average sale price. The Reporting Persons hereby undertake
to provide full information regarding the number of shares and prices at which these transactions, and all other transactions reported
in this 13D/A, were effected upon request to the staff of the Securities and Exchange Commission.
7 This transaction was executed in multiple trades at prices
ranging from $0.35 to $0.36, the price reported above reflects the weighted average sale price.
8 This transaction was executed in multiple trades at prices
ranging from $0.35 to $0.37, the price reported above reflects the weighted average sale
price.
CUSIP No. 483119103
EXHIBIT 1
JOINT FILING AGREEMENT
This Joint Filing Agreement, dated as of May 31,
2022, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing
are collectively referred to herein as the “Filers”).
Each of the Filers may be required to file with
the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, par value $0.001
per share of Kala Pharmaceutics, Inc. beneficially owned by them from time to time.
Pursuant to and in accordance with Rule 13(d)(1)(k)
promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G
and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement
as an exhibit to such statement, as required by such rule.
This Joint Filing Agreement may be terminated
by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.
Executed and delivered as of the date first above
written.
RA CAPITAL MANAGEMENT, L.P.
| Title: | Authorized Signatory |
PETER KOLCHINSKY
/s/ Peter Kolchinsky
RAJEEV SHAH
/s/ Rajeev Shah
RA CAPITAL HEALTHCARE FUND, L.P.
| By: | RA Capital Healthcare Fund GP, LLC |
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Sep 2024 to Oct 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Oct 2023 to Oct 2024